Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES
Pharmas Market Video Gallery
The FDA is holding meetings into big pharma's possible use of social media to sell their products. CNBC's Mike Huckman h...
Big pharma is embracing social media, but how much can or should a tightly regulated sector be able to say on Facebook o...
PHARMA WATCH LIST
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

SPECIAL REPORT


Current DateTime: 01:12:06 12 Nov 2009
LinksList Documentid: 32984624

PHARMA'S MARKET VIDEO

» More

Current DateTime: 01:12:06 12 Nov 2009
LinksList Documentid: 31171988
Expiration DateTime: 11/12/2009 1:15:08 PM

RSS FEED

» Help

Current DateTime: 01:12:07 12 Nov 2009
LinksList Documentid: 31171995
powered by digg

Pharma's Market

Text Size
Apr.01
11:03 AM ET

Given investor reaction to the Vytorin/Zetia news yesterday, you might draw the conclusion the huge cholesterol drug franchise might be doomed.

Sure, analysts say, prescriptions and sales are gonna go down some more, but they're not going to zero. The drug may not have been effective as had been hoped against a key heart disease measure, but it did lower bad cholesterol, triglycerides and a marker for heart attack risk more than Zocor alone.

And MRK [MRK  Loading...      ()   ] and SGP [SGP  Loading...      ()   ] are already trying to promote that fact. Check out the two-page ad the companies took out in today's USA Today sports section. (The first page is the true ad, the second page is all the fine print on the label about side effects and stuff.)

What I think is most notable about the message is that they come right out with it--and in boldface type, no less:  "VYTORIN has not been shown to reduce heart attacks or strokes more than Zocor alone."
Souce: USA Today

On the flip side Pfizer [PFE  Loading...      ()   ] has taken out a big ad in the Newark Star-Ledger (most of the large drug companies have major operations or their HQ in Jersey and tens of thousands of employees live there) for the past couple days. The copy says: "Now you know. There's an important difference between Vytorin, Zetia, and Lipitor. Unlike Vytorin and Zetia, Lipitor is FDA-approved to reduce the risk of heart attacks, strokes...."

And now even the editorial cartoonists are jumping into the fray. Today's Star-Ledger opinion page features this little gem on Vytorin: "Take twice a day for no good reason. Side effects: falling stock prices, reduced executive bonuses, uncontrollable CEO weeping, job loss."
Star Ledger

But in all seriousness, the Vytorin/Zetia aftermath may not be Schering's only challenge. There's a slew of analyst commentary and at least a couple of upgrades on Vertex Pharmaceuticals [VRTX  Loading...      ()   ] this morning.

What does that have to do with SGP? Well, the companies are racing to get new drugs approved for hepatitis c and based on new data many analysts are saying it looks like VRTX's drug might be better than they thought it was and possibly better than Schering's.

In an exclusive interview with Jim Cramer on "Mad Money" last night SGP CEO Fred Hassan said, "This is a broad, strong company."

Its strength is certainly being put to the test.

Questions?  Comments? 

© 2009 CNBC, Inc. All Rights Reserved

Tools:
PrintEmailAdd This share icon
Next Post
  • digg share
ADD COMMENTS
Remaining characters


Current DateTime: 12:27:36 12 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 11:27:46 12 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 11:27:46 12 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:00:12 12 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters